More About Chris Jeffers
Chris is a 25+ year veteran of healthcare and biotech. Beginning his career Chris ran clinical laboratories for the U.S. Air Force and civilian hospitals in the early 90’s. Since then, he has held various roles including CEO, General Counsel, Vice President of Drug Discovery, Managing Director and has served as outside counsel to hundreds of life science companies ranging from big pharma to individual inventors.
Chris is the co-Founder and CEO of Hibiscus BioTechnology, a Venture Studio, and is the CEO of Mayflower BioVentures – a collaboration between Hibiscus and the Mayo Clinic focused on the formation of new cell and gene therapy companies. Before co-founding Hibiscus Chris was a partner in the Washington, DC office of Mintz Levin, where he led a multidisciplinary team specializing in representing biotech and pharma companies in complex corporate, financing and commercial transactions as well as general business advising.
Chris received his Ph.D. training in Biochemistry and Biophysics at Rice University and the University of Houston, where he was a National Institutes of Health Predoctoral Fellow. Following his Ph.D. training Chris was an NIH Postdoctoral Fellow at The Johns Hopkins University School of Medicine where he studied the structure of the Cystic Fibrosis Transmembrane Conductance Receptor (CFTR). In addition, Chris obtained his law degree from Georgetown University. Bringing years of startup experience to Hibiscus Chris was the founder of Sendero Biosciences, Primera Therapeutics, Regio Biosciences, FirstStage Bioventures, Seguro Surgical and EncephRx, and was the General Counsel and V.P. of Drug Discovery at Alba Therapeutics. In addition to serving as outside General Counsel to numerous biotech companies including Viela Bio and NexImmune, Chris holds adjunct faculty appointments in the School of Business and Whiting School of Engineering at Johns Hopkins University.